About Me

header ads

Study finds that patients with heart failure with improved ejection fraction benefit from the SGLT2 inhibitor dapagliflozin

With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment. But despite this improvement in the ability of their hearts to pump, these patients with so called heart failure with improved ejection fraction (HFimpEF) remain at high risk for adverse outcomes.

from News Medical Medical Research News Feed https://ift.tt/hM3C6XV

Post a Comment

0 Comments